Obesity, which has currently reached pandemic dimensions, is usually accompanied by
diabetes mellitus type 2 (T2DM). These two conditions share common pathophysiological …

Non‐alcoholic fatty liver disease (NAFLD) is a disorder characterized by excessive
accumulation of fat in the liver that can progress to liver inflammation (non‐alcoholic …

Background A significant proportion of premature deaths globally are related to metabolic
diseases in young adults. We examined the global trends and mortality of metabolic …

Severe side effects of chemotherapeutic and anti-diabetic drugs for cancer cells and type 2
diabetes (T2D) type and emerging drug resistance in pathogenic microorganisms …

Background The prevalence of type 2 diabetes mellitus (T2DM) has increased over the past
decades. Diabetic cardiomyopathy (DCM) is the leading cause of death in T2DM patients …

Olea europaea L. folium merits further exploration of the potential of its substrates for
therapeutic supplements. Quantitative and qualitative analyses were conducted on samples …

Metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and non-
alcoholic fatty liver disease (NAFLD)–henceforth named metabolic dysfunction-associated …

Chiglitazar is a novel peroxisome proliferator-activated receptor (PPAR) pan-agonist, which
passed phase III clinical trials and was newly approved in China for use as an adjunct to diet …

Background Atherosclerosis (AS) is a progressive chronic disease. Currently, cardiovascular
diseases (CVDs) caused by AS is responsible for the global increased mortality …

The pharmacotherapy of type 2 diabetes mellitus (T2DM) has markedly evolved in the last
two decades. Classical antidiabetic agents (sulphonylureas, metformin, insulin) are now in …